Literature DB >> 22860005

TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.

Orla M Casey1, Lei Fang, Paul G Hynes, Wassim G Abou-Kheir, Philip L Martin, Heather S Tillman, Gyorgy Petrovics, Hibah O Awwad, Yvona Ward, Ross Lake, Luhua Zhang, Kathleen Kelly.   

Abstract

Genomic rearrangements commonly occur in many types of cancers and often initiate or alter the progression of disease. Here we describe an in vivo mouse model that recapitulates the most frequent rearrangement in prostate cancer, the fusion of the promoter region of TMPRSS2 with the coding region of the transcription factor, ERG. A recombinant bacterial artificial chromosome including an extended TMPRSS2 promoter driving genomic ERG was constructed and used for transgenesis in mice. TMPRSS2-ERG expression was evaluated in tissue sections and FACS-fractionated prostate cell populations. In addition to the anticipated expression in luminal cells, TMPRSS2-ERG was similarly expressed in the Sca-1(hi)/EpCAM(+) basal/progenitor fraction, where expanded numbers of clonogenic self-renewing progenitors were found, as assayed by in vitro sphere formation. These clonogenic cells increased intrinsic self renewal in subsequent generations. In addition, ERG dependent self-renewal and invasion in vitro was demonstrated in prostate cell lines derived from the model. Clinical studies have suggested that the TMPRSS2-ERG translocation occurs early in prostate cancer development. In the model described here, the presence of the TMPRSS2-ERG fusion alone was not transforming but synergized with heterozygous Pten deletion to promote PIN. Taken together, these data suggest that one function of TMPRSS2-ERG is the expansion of self-renewing cells, which may serve as targets for subsequent mutations. Primary prostate epithelial cells demonstrated increased post transcriptional turnover of ERG compared to the TMPRSS2-ERG positive VCaP cell line, originally isolated from a prostate cancer metastasis. Finally, we determined that TMPRSS2-ERG expression occurred in both castration-sensitive and resistant prostate epithelial subpopulations, suggesting the existence of androgen-independent mechanisms of TMPRSS2 expression in prostate epithelium.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22860005      PMCID: PMC3408501          DOI: 10.1371/journal.pone.0041668

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  43 in total

1.  Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells.

Authors:  Peter C Hollenhorst; Mary W Ferris; Megan A Hull; Heejoon Chae; Sun Kim; Barbara J Graves
Journal:  Genes Dev       Date:  2011-10-15       Impact factor: 11.361

Review 2.  Revisiting the concept of cancer stem cells in prostate cancer.

Authors:  Z A Wang; M M Shen
Journal:  Oncogene       Date:  2010-11-29       Impact factor: 9.867

3.  Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways.

Authors:  Y Ward; W Wang; E Woodhouse; I Linnoila; L Liotta; K Kelly
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

4.  Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis.

Authors:  Jacques Lapointe; Chunde Li; Craig P Giacomini; Keyan Salari; Stephanie Huang; Pei Wang; Michelle Ferrari; Tina Hernandez-Boussard; James D Brooks; Jonathan R Pollack
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

5.  Delineation of TMPRSS2-ERG splice variants in prostate cancer.

Authors:  Ying Hu; Albert Dobi; Taduru Sreenath; Christopher Cook; Atekelt Y Tadase; Lakshmi Ravindranath; Jennifer Cullen; Bungo Furusato; Yongmei Chen; Rajesh L Thangapazham; Ahmed Mohamed; Chen Sun; Isabell A Sesterhenn; David G McLeod; Gyorgy Petrovics; Shiv Srivastava
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

6.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Authors:  Brett S Carver; Jennifer Tran; Anuradha Gopalan; Zhenbang Chen; Safa Shaikh; Arkaitz Carracedo; Andrea Alimonti; Caterina Nardella; Shohreh Varmeh; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

7.  Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.

Authors:  Jianghua Wang; Yi Cai; Wendong Yu; Chengxi Ren; David M Spencer; Michael Ittmann
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

8.  Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.

Authors:  Changmeng Cai; Hongyun Wang; Youyuan Xu; Shaoyong Chen; Steven P Balk
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

9.  ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.

Authors:  Ping Chi; Yu Chen; Lei Zhang; Xingyi Guo; John Wongvipat; Tambudzai Shamu; Jonathan A Fletcher; Scott Dewell; Robert G Maki; Deyou Zheng; Cristina R Antonescu; C David Allis; Charles L Sawyers
Journal:  Nature       Date:  2010-10-03       Impact factor: 49.962

10.  ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.

Authors:  B Furusato; S-H Tan; D Young; A Dobi; C Sun; A A Mohamed; R Thangapazham; Y Chen; G McMaster; T Sreenath; G Petrovics; D G McLeod; S Srivastava; I A Sesterhenn
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-06-29       Impact factor: 5.554

View more
  28 in total

1.  microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients.

Authors:  Ashraf Bakkar; Mohammed Alshalalfa; Lars F Petersen; Hatem Abou-Ouf; Amal Al-Mami; Samar A Hegazy; Felix Feng; Reda Alhajj; Krikor Bijian; Moulay A Alaoui-Jamali; Tarek A Bismar
Journal:  Mol Biol Rep       Date:  2016-02-23       Impact factor: 2.316

2.  TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.

Authors:  Z Mounir; F Lin; V G Lin; J M Korn; Y Yu; R Valdez; O H Aina; G Buchwalter; A B Jaffe; M Korpal; P Zhu; M Brown; R D Cardiff; J L Rocnik; Y Yang; R Pagliarini
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

Review 3.  The ETS family of oncogenic transcription factors in solid tumours.

Authors:  Gina M Sizemore; Jason R Pitarresi; Subhasree Balakrishnan; Michael C Ostrowski
Journal:  Nat Rev Cancer       Date:  2017-04-28       Impact factor: 60.716

4.  PREVENTING THE CHROMOSOMAL TRANSLOCATIONS THAT CAUSE CANCER.

Authors:  Robert Hromas; Elizabeth Williamson; Suk-Hee Lee; Jac Nickoloff
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

5.  Wnt signaling in castration-resistant prostate cancer: implications for therapy.

Authors:  Noriko N Yokoyama; Shujuan Shao; Bang H Hoang; Dan Mercola; Xiaolin Zi
Journal:  Am J Clin Exp Urol       Date:  2014-04-15

Review 6.  From genomics to functions: preclinical mouse models for understanding oncogenic pathways in prostate cancer.

Authors:  Chuan Yu; Kevin Hu; Daniel Nguyen; Zhu A Wang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

7.  ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.

Authors:  Liem T Nguyen; Maria S Tretiakova; Mark R Silvis; Jared Lucas; Olga Klezovitch; Ilsa Coleman; Hamid Bolouri; Vassily I Kutyavin; Colm Morrissey; Lawrence D True; Peter S Nelson; Valeri Vasioukhin
Journal:  Cancer Cell       Date:  2015-06-08       Impact factor: 31.743

Review 8.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

Review 9.  Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications.

Authors:  Qu Deng; Dean G Tang
Journal:  Endocr Relat Cancer       Date:  2015-08-18       Impact factor: 5.678

10.  Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

Authors:  Michael Ittmann; Jiaoti Huang; Enrico Radaelli; Philip Martin; Sabina Signoretti; Ruth Sullivan; Brian W Simons; Jerrold M Ward; Brian D Robinson; Gerald C Chu; Massimo Loda; George Thomas; Alexander Borowsky; Robert D Cardiff
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.